{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nan FY"],"funding":["Zhenjiang Clinical Research Center of Hematology","Medical Innovation Team of Jiangsu Province","Scientific Research Project of The Fifth 169 Project of Zhenjian","National Natural Science Foundation of China","Social Development Foundation of Zhenjiang"],"pagination":["5283-5296"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8335806"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(15)"],"pubmed_abstract":["It was previously reported that PRR34-AS1 was overexpressed in some solid tumors. PRR34-AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real-time quantitative PCR (RQ-PCR) to explore the expression characteristics of PRR34-AS1 in AML. In addition, the correlation between the expression of PRR34-AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34-AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34-AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34-AS1 after induction chemotherapy. Furthe"],"journal":["Cancer medicine"],"pubmed_title":["Abnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia."],"pmcid":["PMC8335806"],"funding_grant_id":["81900166","SH2019065","SH2019067","SS2018009","81970118","81900163","CXTDB2017002"],"pubmed_authors":["Qian J","Gu Y","Nan FY","Lin J","Zhou JD","Ma JC","Sun GK","Leng JY","Xu ZJ","Zhang TJ"],"additional_accession":[]},"is_claimable":false,"name":"Abnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.","description":"It was previously reported that PRR34-AS1 was overexpressed in some solid tumors. PRR34-AS1 promoter was shown to have a differential methylation region (DMR), and was hypomethylated in acute myeloid leukemia (AML). Therefore, the present study used real-time quantitative PCR (RQ-PCR) to explore the expression characteristics of PRR34-AS1 in AML. In addition, the correlation between the expression of PRR34-AS1 and clinical prognosis of AML was determined. The findings of this study indicated that high PRR34-AS1 expression was bound up with shorter overall survival (OS) in AML patients (p = 0.002). Moreover, patients with high expression of PRR34-AS1 had significantly lower complete remission (CR) rate compared with those with low expression of PRR34-AS1 after induction chemotherapy. Furthe","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-05-08T16:57:33.414Z","creation":"2022-02-11T06:05:04.27Z"},"accession":"S-EPMC8335806","cross_references":{"pubmed":["34227248"],"doi":["10.1002/cam4.4085"]}}